Cediranib effect on metastatic alveolar soft part sarcoma
Summary:
Analysis of metastatic alveolar soft part sarcoma (ASPS) biopsies from patients treated with cediranib, a small-molecule inhibitor of vascular endothelial growth factor receptors. Results provide insight into molecular mechanisms underlying the substantial single-agent activity of cediranib on ASPS.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Kummar S, Allen D, Monks A, Polley EC et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol 2013 Jun 20;31(18):2296-302. PMID: 23630200
